Blocking the bradykinin response: Pharmacodynamics and safety of icatibant, a potent and selective bradykinin B2 receptor antagonist

  • Jens Zimmermann, Bernd Rosenkranz, Françoise Brunner-Ferber, Jochen Knolle
  • Molecular Immunology, October 2008, Elsevier
  • DOI: 10.1016/j.molimm.2008.08.185

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Professor Bernd Rosenkranz